Therapeutic | Oportuzumab |
Target | EPCAM |
Heavy Chain | EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | scFv |
Isotype | na |
Highest Clinical Trial (June '19) | Preregistration |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | University of Zurich, National Cancer Institute (USA), Sesen Bio, Viventia Biotechnologies |
Conditions Approved | na |
Conditions Active | Bladder cancer, Head and neck cancer |
Conditions Discontinued | Liver cancer, Ovarian cancer |
Notes |